TIVDAK
Drug
Seagen Inc.
Total Payments
$12.3M
Transactions
10,843
Doctors
3,582
Companies
4
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3.0M | 2,691 | 1,318 |
| 2023 | $3.8M | 3,188 | 1,466 |
| 2022 | $3.6M | 4,183 | 1,747 |
| 2021 | $1.9M | 781 | 438 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9.4M | 933 | 76.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.2M | 343 | 10.0% |
| Consulting Fee | $848,861 | 289 | 6.9% |
| Travel and Lodging | $301,224 | 1,143 | 2.5% |
| Food and Beverage | $257,209 | 8,100 | 2.1% |
| Grant | $100,000 | 1 | 0.8% |
| Honoraria | $58,476 | 12 | 0.5% |
| Space rental or facility fees (teaching hospital only) | $45,450 | 12 | 0.4% |
| Education | $5,412 | 10 | 0.0% |
Payments by Type
Research
$9.4M
933 transactions
General
$2.8M
9,910 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS | PFIZER INC. | $2.3M | 0 |
| Open Label Phase 2 Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors | Seagen Inc. | $2.2M | 0 |
| A Randomized, Open-Label, Phase 3 Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer | Seagen Inc. | $2.2M | 0 |
| Nonclinical Evaluation of Tisotumab Vedotin in CNS Pediatric Malignancies | Seagen Inc. | $898,527 | 0 |
| A PHASE 1B/2 OPEN-LABEL TRIAL OF TISOTUMAB VEDOTIN HUMAX-TF-ADC MONOTHERAPY AND IN COMBINATION WITH OTHER AGENTS IN SUBJECTS WITH RECURRENT OR STAGE IVB CERVICAL CANCER | Genmab U.S., Inc. | $659,919 | 0 |
| Open Label Phase 2 Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen | Seagen Inc. | $496,650 | 0 |
| A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer | Genmab U.S., Inc. | $222,240 | 0 |
| A Single arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer | Genmab U.S., Inc. | $63,938 | 0 |
| A Phase 1 Study of SGN-STNV in Advanced Solid Tumors | Seagen Inc. | $62,389 | 0 |
| The clinical potential of Tisotumab vedotin-tftv in adult-type diffuse gliomas | Seagen Inc. | $55,261 | 0 |
| A RANDOMIZED OPENLABEL PHASE 3 TRIAL OF TISOTUMAB VEDOTIN VS INVESTIGATORS CHOICE CHEMOTHERAPY IN SECOND OR THIRDLINE RECURRENT OR METASTATIC CERVICAL CANCER | PFIZER INC. | $50,376 | 0 |
| TUCATINIB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $16,000 | 5 |
| A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies | Seagen Inc. | $13,398 | 0 |
| OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR PATIENTS WITH PLATINUMRESISTANT OVARIAN CANCER WITH A SAFETY RUNIN OF A DOSEDENSE REGIMEN | PFIZER INC. | $8,218 | 0 |
| TIVDAK CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,560 | 2 |
| A SINGLE ARM, MULTICENTER, INTERNATIONAL TRIAL OF TISOTUMAB VEDOTIN (HUMAX-TF-ADC) IN PREVIOUSLY TREATED, RECURRENT OR METASTATIC CERVICAL CANCER | Genmab U.S., Inc. | $750.00 | 0 |
Top Doctors Receiving Payments for TIVDAK
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Houston, TX | $9.5M | 954 |
| , CRNP | Family | Pittsburgh, PA | $353,044 | 778 |
| , PNP | Pediatrics | Denver, CO | $154,929 | 293 |
| , MD | Gynecologic Oncology | Phoenix, AZ | $153,214 | 110 |
| , MD | Obstetrics & Gynecology | Hershey, PA | $110,883 | 86 |
| , MD | Obstetrics & Gynecology | San Francisco, CA | $108,427 | 60 |
| , MD | Specialist | Seattle, WA | $99,164 | 76 |
| , M.D | Gynecologic Oncology | Fort Lauderdale, FL | $97,486 | 68 |
| , M.D | Gynecologic Oncology | Mesa, AZ | $84,702 | 53 |
| , MD | Gynecologic Oncology | Pittsburgh, PA | $75,700 | 63 |
| , MD | Obstetrics & Gynecology | Richmond, VA | $75,473 | 48 |
| , MD | Obstetrics & Gynecology | Grosse Pointe Woods, MI | $73,894 | 47 |
| , M.D | Gynecologic Oncology | San Antonio, TX | $72,638 | 61 |
| , MD | Gynecologic Oncology | Orlando, FL | $63,810 | 36 |
| Chirag Shah | Gynecologic Oncology | Seattle, WA | $63,781 | 37 |
| , M.D | Obstetrics & Gynecology | Richmond, VA | $58,427 | 35 |
| , M.D | Gynecologic Oncology | Fort Lauderdale, FL | $58,066 | 38 |
| , MD | Gynecologic Oncology | Philadelphia, PA | $48,655 | 42 |
| , CNP | Women's Health | Columbus, OH | $40,998 | 76 |
| , MD | Obstetrics & Gynecology | Charlotte, NC | $40,224 | 29 |
| , M.D | Gynecologic Oncology | Chicago, IL | $39,190 | 31 |
| , M.D | Gynecologic Oncology | Orange, CA | $34,182 | 20 |
| , M.D | Ophthalmology | Houston, TX | $32,923 | 10 |
| , D.O | Obstetrics & Gynecology | Kansas City, MO | $29,797 | 26 |
| , MD | Obstetrics & Gynecology | Huntington, WV | $29,312 | 28 |
Ad
Manufacturing Companies
- Seagen Inc. $8.0M
- PFIZER INC. $3.0M
- Genmab U.S., Inc. $1.2M
- ARRAY BIOPHARMA INC $349.53
Product Information
- Type Drug
- Total Payments $12.3M
- Total Doctors 3,582
- Transactions 10,843
About TIVDAK
TIVDAK is a drug associated with $12.3M in payments to 3,582 healthcare providers, recorded across 10,843 transactions in the CMS Open Payments database. The primary manufacturer is Seagen Inc..
Payment data is available from 2021 to 2024. In 2024, $3.0M was paid across 2,691 transactions to 1,318 doctors.
The most common payment nature for TIVDAK is "Unspecified" ($9.4M, 76.8% of total).
TIVDAK is associated with 16 research studies, including "OPEN LABEL PHASE 2 STUDY OF TISOTUMAB VEDOTIN FOR LOCALLY ADVANCED OR METASTATIC DISEASE IN SOLID TUMORS" ($2.3M).